|
Kenneth A. Foon, M.D. is the Co-Director of Biological Therapy and Hematologic Malignancy Program at the University of Pittsburgh Cancer Institute (UPCI). Dr. Foon is also the former Director of Clinical Development for Oncology at Abgenix, Inc. and the former Head of the Monoclonal Antibody Section at the Division of Cancer Treatment at the National Cancer Institute. Previously, he held positions as Clinical Professor of Medicine at Stanford University Medical Center, and at University of Michigan, Roswell Park Cancer Institute, the Scripps Research Institute and the University of Kentucky. Dr. Foon’s considerable expertise in both oncology antibodies and clinical development gives Automated Cell a powerful voice of experience as it develops its oncology antibody discovery platform and the lead candidates that it generates. | 